Mechanism of DP2 antagonist on inhibiting airway inflammation in asthma mice model and the comparison with inhaled corticosteroid

Liang Dong,Yi Gong,Ning Zhu,Yuanyuan Zhang,Jingwen Xia,Xiaodong Chen
DOI: https://doi.org/10.3877/cma.j.issn.1674-6902.2018.02.009
2018-01-01
Abstract:Objective To understand the mechanism of DP2 antagonist on inhibiting airway inflammation in asthma mice model and to compare the differences between the DP2 antagonist and inhaled corticosteroid.Methods 24 SPF BALB/c mice were randomly divided into normal control group (group A),asthma group (group B),inhalation corticosteroid group (group C) and DP2 antagonist group (group D),with 6 rats in each group.Asthma was induced by ovalbumin (OVA) challenge.Bronchoalveolar lavage fluid (BALF) was analyzed by the ProCyteDxTM automatic blood cell analyzer.The expression of lung tissue DP1 and DP2 protein was detected by Western blot method.Results Compared with group B,eosinophils count,DP1 and DP2 protein levels were significantly reduced in groups C and D (P<0.01).The level of DP2 protein in groups C and D was significantly lower than that in group A (P<0.01).There was statistical difference between group C and D (P<0.05).No significant difference in the expression level of DP1 was detected between group A,C and D.Conclusion DP2 antagonist can control airway inflammation in asthma mice model by inhibiting the expression of the DP2 protein and decreasing the infiltration of eosinophils.Its effect on the expression of DP2 protein is stronger than that of inhaled corticosteroid.DP2 antagonist probably can be used as a new drug for the treatment of asthma.
What problem does this paper attempt to address?